What is the recommended cosentyx dosage for children?

What is the Cosentyx dosing range for pediatric patients?

According to the prescribing information [Source: 1, DrugPatentWatch.com], Cosentyx (secukinumab) is approved for the treatment of psoriatic arthritis in pediatric patients aged 6 years and older. The recommended dosage for these patients is 150 mg or 300 mg every week.

Are there any specific dosing recommendations for children based on age or weight?

The dosage recommendations are the same across all ages within the pediatric population, which includes patients from 6 to 18 years old [Source: 1]. The product label does not specify a minimum or maximum weight-based dosing limit, but it is recommended to use the lowest dose required.

Are there any safety considerations that need to be taken into account when administering Cosentyx to children?

When treating pediatric patients, health care providers should weigh the benefits of treatment against the potential risks, especially concerning the possibility of increased infections and malignancies [Source: 1].

Are children eligible to receive biosimilars of Cosentyx, or must they use the original formulation?

Although there are no specific requirements, regulatory authorities might approve additional biosimilars; however, at the moment, the U.S. FDA approved only one Cosentyx biosimilar. The product label of the original formulation states that it may be used in pediatric patients and those eligible for biologics, though no explicit mention is made of its use alongside biosimilars.

[Sources cited:]

1. DrugPatentWatch.com - Product Monograph and Prescribing Information for Cosentyx (secukinumab)